Repertoire Immune Medicines Inc.

With headlines dominated by Merck KGaA/Springworks deal, smaller companies make deals to advance programs

Back to School 2024 identifies the target classes emerging in inflammation and immunology, and the technologies used to find them

Plus: Regeneron, Mammoth to make CRISPR-based gene editing therapies, and updates from Vertex-TreeFrog, Ono-Deciphera and more

Plus: Dyne shares slip with CEO departing, and updates from Ardelyx and ProKidney

Pair of well-funded Flagship portfolio companies will unite in Sail Biomedicines to develop programmable medicines

Plus Huang becomes Zai CSO and updates from Aadi, VectorY, Fulcrum and Xenon

Plus new CMO at Boehringer Ingelheim, and updates from Repertoire, Atsena, TAAV and more

The Cygnal-Inzen mashup is taking a microenvironment-focused approach to cancer, fibrosis and autoimmunity

BioCentury’s roundup of translational news

SITC provides a snapshot of how companies are enhancing TIL and TCR therapies